Products
Rurioctocog alfa pegol was approved in many countries in 2016 as a lyophilizate and solvent for the preparation of a solution for intravenous injection (Adynovi).
Structure and properties
Rurioctocog alfa pegol is a pegylated recombinant human blood coagulation factor VIII (octocog alfa). Pegylation results in a prolonged half-life.
Effects
Rurioctocog alfa pegol (ATC B02BD02) is administered as a replacement for endogenous factor VIII. Factor VIII plays an important role in blood clotting.
Indications
For prevention and treatment of bleeding in pretreated patients with hemophilia A (congenital factor VIII deficiency).
Dosage
According to the SmPC. The drug is administered as intravenous.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
There are no known drug-drug interactions.
Adverse effects
The most common possible adverse effects include headache. Occasionally, diarrhea, nausea, and flushing may occur.
